A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors

Breast Cancer Clinical Trial

Official title:

An Open, Single-armed, Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05961111
• Other study ID #: LYCH-R130
• Status: Recruiting
• Phase: Early Phase 1
• Start date: June 24, 2023
• Est. completion date: June 2026

Study information

• Verified date: July 2023
• Source: Shanghai Yunying Medical Technology
• Contact: Feng Pan
• Phone: +8613764868528
• Email: pf[@]jxyymedtech.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: June 2026
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Patients with solid tumors clearly diagnosed by histology and/or cytology.

2. Failure of standard treatment or patient unwillingness to receive other antitumor therapy.

3. Age 18 to 75 years.

4. Subjects with ECoG score of 0-2.

5. Expected survival of 3 months or more.

6. Have at least one measurable lesion (according to RECIST 1.1 criteria) that is amenable to intratumoral or intraperitoneal drug delivery.

7. Subjects must have appropriate organ function, and laboratory tests during the screening period must meet the following requirements: a) absolute neutrophil count (ANC) = 1.5 × 109/L, platelets (PLT) = 80 × 109/L, and hemoglobin (Hb) = 85 g/L; b) serum creatinine (Cr) and blood urea nitrogen (BUN) within 1.5 times the upper limit of normal values; c) serum c) serum total bilirubin (TBIL) = 2 times the upper limit of normal values; d) glutamic aminotransferase (ALT) and glutamic oxalacetic aminotransferase (AST) = 2.5 times the upper limit of normal values; subjects with liver metastases do not exceed 5 times the upper limit of normal values; e) activated partial thromboplastin time (APTT), prothrombin time (PT) within 1.5 times the upper limit of normal values.

8. No absolute or relative centasis contraindiction.

9. Eligible patients of childbearing potential must agree to use a reliable method of contraception with their partner for the duration of the trial and for at least 180 days after the last dose; female patients of childbearing potential must have a negative urine pregnancy test within 7 days prior to enrollment.

10. Subjects voluntarily sign an informed consent form and are in good compliance.

Exclusion Criteria:

1. Have had any serious adverse reactions associated with immunotherapy.

2. Subjects with any severe and/or uncontrolled disease, including: a) poorly controlled hypertension (systolic blood pressure = 150 mmHg or diastolic blood pressure = 100 mmHg); b) suffering from class I or higher myocardial ischemia or myocardial infarction, arrhythmia (QTc = 470 ms and = grade 2 congestive heart failure (New York Heart Association (NYHA) classification); c) active or uncontrolled severe infection (= CTCAE grade 2 infection); d) Patients with previous organ transplantation, bone marrow transplantation (hematopoietic stem cell transplantation) and severe immune deficiency; e) Urine routine suggesting urine protein =++ and confirmed 24-hour urine protein quantification > 1.0 g.

3. Patients with past history of type I diabetes mellitus or HIV.

4. Severe abnormalities in thyroid and cortisol testing; active, known or suspected autoimmune disease requiring systemic therapy.

5. Patients with severe prior interstitial lung changes (as determined by the investigator).

6. Patients with active tuberculosis and a strong positive OT test.

7. Patients with active bleeding or severe coagulation dysfunction.

8. Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose.

9. Have not recovered to CTCAE 4.0 grade rating 0 or 1 level of toxicity after previous antineoplastic therapy.

10. Current active hepatitis B, active hepatitis C, immunodeficiency virus or other active infection of clinical significance.

11. Patients who have undergone surgery of grade 3 or higher or whose surgical wounds have not healed within 4 weeks prior to enrollment.

12. Pregnant, lactating and planning to have children within six months.

13. Subjects who, in the judgment of the investigator, are unsuitable for participation in this trial for any reason.

Related Conditions & MeSH terms

• Brain Cancer
• Brain Neoplasms
• Breast Cancer
• Carcinoma
• Digestive Cancer
• Gynecologic Cancer
• Head and Neck Cancer
• Kidney Cancer
• Kidney Neoplasms
• Lung Cancer
• Melanoma
• Sarcoma

Intervention

Drug:
• Recombinant oncolytic herpes simplex virus type 1 (R130)
R130, a modified herpes simplex virus-? (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11

Locations

Country	Name	City	State
China	Linyi Central Hospital	Linyi	Shandong

Sponsors (2)

Lead Sponsor	Collaborator
Shanghai Yunying Medical Technology	Linyi Central Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Subject incidence of adverse events	To characterize the safety profile of R130 injection in patients with advanced solid tumors as measured by the incidence of Grade = 3 Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE v5.0),such as fever, fatigue, flu like symptoms, chills, Injection site reaction,etc.	Up to 6 months
Primary	Subject incidence of laboratory abnormalities		Up to 1 month
Primary	Systemic Immune Response	Detection of increased systemic immune Response markers in sera (IL2,IL4,IL6,IL8,IL10,TNFa,IFN?, etc.) and peripheral blood mononuclear cells by multi-Color fluorescence-activated cell sorting (FACS)	Up to 6 months
Secondary	Disease Assessment for Disease Control Rate	CT will be performed to evaluate the efficacy endpoints of DCR by the investigator with RECIST v1.1 and iRECIST. DCR (proportion of patients) = with CR +PR +SD /CR + PR +SD + PD.	Every 10 weeks for 12 months
Secondary	Disease Assessment for Duration of Response	The time length between the first confirmed objective response per RECIST 1.1 to the treatment and the subsequent disease progression per RECIST 1.1	Every 10 weeks for 12 months
Secondary	Quality of Life Assessment	Comparison of patients' quality of life before and after R130 treatment as assessed by the EORTC QLQ-30 (V3.0).	Every 6 weeks for 12 months